Excuse me, what disease can people with thymopentin get?

Commodity name access

The main component of this product is thymopentin. Accessories: sodium chloride, sodium citrate.

This product is a colorless and clear liquid.

Indications This product is suitable for: patients with malignant tumor have low immune function caused by radiotherapy and chemotherapy.

There are literatures at home and abroad showing that thymopentin is used in the following situations, but there is no information on the safety and effectiveness of drugs with a dose above 1mg in China:

(1) for1chronic hepatitis B patients over 8 years old. Because 18 years old, the thymus began to shrink and the cellular immune function declined.

(2) All kinds of primary or secondary T cell deficiency.

(3) Some autoimmune diseases (such as rheumatoid arthritis and systemic lupus erythematosus).

(4) Various diseases with low cellular immune function.

(5) Adjuvant treatment of tumor.

Measuring tool 1 ml: 10 mg.

Usage and dosage intramuscular injection or subcutaneous injection. According to the literature from Italy, the dosage of this product can be 50 mg per day.

Note: (1) Please follow the doctor's advice when using this product.

(2) There is no information about the safety and effectiveness of such a large dose of this product in China.

counteraction

(1) Some patients have adverse reactions such as nausea, fever, dizziness, chest tightness and fatigue, and a few patients occasionally feel sleepy.

(2) The ALT level in patients with chronic hepatitis B may increase for a short time. If there is no warning of liver failure, they can continue to use the product.

It is forbidden for those who have allergic reaction to this product or need immunosuppression in the early stage of organ transplantation.

Matters needing attention

1. This product plays a therapeutic role by enhancing the immune function of patients, so it should not be used for patients receiving immunosuppressive treatment (such as organ transplant recipients) unless the benefits brought by treatment obviously outweigh the risks.

2. Patients with chronic hepatitis B should regularly check their liver function during treatment.

3./kloc-use with caution in patients under 0/8 years old.

The study on the fertility of pregnant women and lactating women shows that there is no difference in the influence of abnormal embryos between the control group and the treatment group. It is not known whether this medicine is harmful to embryos or affects fertility. So this medicine can only be given to pregnant women when it is very necessary. At present, although it has not been confirmed that this product is excreted by human milk, lactating women should use it with special caution.

China/KLOC-Children under 0/8 years old still lack sufficient safety and validity data.

At present, there is still a lack of data on the effectiveness and safety of medication for elderly patients in China. Follow the doctor's advice if necessary.

drug interaction

1. This product is used in combination with a variety of commonly used drugs, including interferon, anti-inflammatory drugs, antibiotics, hormones, analgesics, antihypertensive drugs, diuretics, drugs for treating cardiovascular diseases, central nervous system drugs, contraceptives, etc., without any interference.

2. The combination of this product and interferon has synergistic effect on improving immune function.

At present, there is no report about drug overdose (treatment or accident) in human body. Animal toxicity test showed that there were no side effects below the dose of 10mg/kg (the highest dose used in current research).

Pharmacology and toxicology

pharmacological action

This product is an immunomodulatory drug, which has the functions of inducing T cell differentiation, promoting the development, maturation and activation of T lymphocyte subsets, and regulating the proportion of T lymphocyte subsets to make them tend to be normal. In vivo, thymopentin promotes the differentiation of T cells by increasing the level of cAMP, and binds to the specific receptors of T cells, thus increasing the level of intracellular GMP, thus inducing a series of intracellular reactions and regulating the immune function of the body.

Toxicological study

Toxicity of repeated administration: Rats and dogs were given subcutaneously for 65438 02 months, with doses of 4,20 and 80mg/kg/ day, respectively. Results: There was obvious local stimulation reaction only at the site of administration. In addition, the high-dose male rats showed an increase in alkaline phosphatase, but there was no related morphological change. The clinical significance of this increase is still unclear.

Pharmacokinetic pharmacokinetic studies show that thymopentin is rapidly degraded by protease and aminopeptidase in human plasma, with a half-life of about 30 seconds, while its retention time in abdominal cavity is longer than that in plasma, reaching 3.5 ~ 7 minutes, and 25% of human saliva cannot be degraded after 10 minutes. Although the metabolism of thymopentin is fast, it quickly acts on the target cells after a single injection, and the in vivo effect can be maintained for several days to weeks through the second messenger.

Storage and shading, 2 ~ 8℃ preservation.

Packed in ampoules, 1 branch/box.

The validity period is tentatively set at 24 months.

The approval number is National Medicine Zhunzi H2006 1226.

Beijing Shiqiao biopharmaceutical co., ltd.